Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis: Margins on upward spiral - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jan 28, 2002

    Novartis: Margins on upward spiral

    Novartis India has declared encouraging results for 3QFY02. Net profits have leapfrogged by more than 100% on a back of sharp spurt in operating margins. However, the growth in topline has slowed down considerably with just 2% growth in the concerned quarter. Subsequent to completion of the demerger of its agribusiness and amalgamation of Ciba CKD Biochem, the company has recast prior period results. The results are thus comparable on a year to year basis.

    (Rs m) 3QFY01 3QFY02 % change 9m FY01 9m FY02 % Change
    Sales 1,230 1,255 2.0% 3,433 3,609 5.1%
    Other Income 56 56 -0.4% 186 164 -11.7%
    Expenditure 1,095 990 -9.5% 3,000 2,968 -1.0%
    Operating Profit (EBDIT) 135 265 95.9% 434 641 47.9%
    Operating Profit Margin (%) 11.0% 21.1%   12.6% 17.8%  
    Interest 35 1 -97.2% 98 30 -69.5%
    Depreciation 22 22 2.3% 65 63 -2.0%
    Profit before Tax 134 297 122.1% 457 712 56.0%
    Extraordinary Items - (35)   - -  
    Tax 46 87 86.4% 149 251 68.5%
    Profit after Tax/(Loss) 87 175 100.6% 308 461 49.9%
    Net profit margin (%) 7.1% 14.0%   9.0% 12.8%  
    No. of Shares (eoy) (m) 31.9 31.7   31.9 31.9  
    Diluted Earnings per share* 10.9 22.1   12.9 19.3  
    P/E (at current price) 10.7   12.2  

    This is third quarter in succession that Novartis has reported a positive surprise on the operating margins. The improvement in margins seems to be on the back of new product introductions, a sharp drop in purchase price of pharma products and closure of its loss making ciba vision business. Novartis incurred a one time VRS cost of Rs 18.8 m during the quarter. Further, other expenditure included Rs 16.6 m provision towards dimunition in the value of investments in US 64. Both the above items being extra-ordinary in nature, we have not taken them into consideration while calculating operating margins.

    % of sales 3QFY01 3QFY02
    Raw Materials 4.1% 3.2%
    Staff Costs 7.4% 7.3%
    Purchase of finished goods 47.0% 47.2%

    The segmental information provided by the company discloses some interesting facts. While margins and sales growth in the pharma business have remained more or less stable, there has been a sharp improvement in margins of its consumer health care business (OTC). The operating margins in this business has jumped from 4.5% for the first half, to 23.9% in the third quarter. Though on a small base, sales also seem to be growing at a fast clip in this business.

    Table Showing Segmentwise operating margins
      3QFY02 9 m FY02
    1HFY02 Sales (Rs m) Margins %* Sales (Rs m) Margins %*
    Pharma 1,018 21.7% 2,987 22.4%
    Consumer Health 144 23.9% 343 12.6%
    Animal Healthcare Business 93 17.5% 279 16.8%
    *- Profit before interest and tax

    At the current market price of Rs 236, the stock trades at 12x its annualised earnings for 9m FY02. The benefits of the restructuring excerise undertaken by the company is evident in the current results. Going forward, it seems that though the company would be able to maintain its margins due to its presence in niche speciality segments, the topline is clearly dependent on new product introductions. The stock is likely to see upside due to positive surprise on the margin front.



    Equitymaster requests your view! Post a comment on "Novartis: Margins on upward spiral". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 01:12 PM


    • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts